A GIP receptor agonist targeting obesity

ZP6590 is an investigational long-acting GIP receptor agonist. The molecule has been designed to be co-formulated with other therapeutic peptides.

Zealand Pharm Lab Part 2 BF3I3151

Development status

We have completed the pre-clinical activities with ZP6590 and the next step in development is to initiate a first-in-human clinical trial. 

In preclinical studies using an in vivo model of diet induced obesity, ZP6590 substantially potentiated the body weight loss effects of GLP-1 monotherapy with semaglutide despite negligible effects of ZP6590 alone. The potentiation of body weight loss resulting from combination therapy in this model was also observed if ZP6590 was added after maximal effect of GLP-1 monotherapy had been achieved. These preclinical results suggest a synergistic potential of this combination in treating obesity.

Some medications, including GLP-1 receptor agonists, are known to induce nausea and vomiting in patients. ZP6590 exerted antiemetic effects in an in vivo model challenged with several emesis-inducing agents. These results suggest the potential therapeutic advantages of combination therapies targeting GIP with other drivers of malaise in the field of weight management.

ZP6590 is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.

Related scientific publications

All scientific publications
  • Obesity Week

    Potent Antiemetic Effect of GIP Analogue ZP6590 in Ferrets, a Gold Standard Model for Emesis Testing

  • Obesity Week

    Anti-obesity Effects of GIP Analogue ZP6590 in Combination with Semaglutide in DIO Mice


More about the disease area

Overweight and obesity are associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation.

  • Learn more
  • Crowd 1